CA2694209C - Azepine derivatives as gamma-secretase inhibitors - Google Patents

Azepine derivatives as gamma-secretase inhibitors Download PDF

Info

Publication number
CA2694209C
CA2694209C CA2694209A CA2694209A CA2694209C CA 2694209 C CA2694209 C CA 2694209C CA 2694209 A CA2694209 A CA 2694209A CA 2694209 A CA2694209 A CA 2694209A CA 2694209 C CA2694209 C CA 2694209C
Authority
CA
Canada
Prior art keywords
methyl
compound
phenyl
compounds
azepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2694209A
Other languages
English (en)
French (fr)
Other versions
CA2694209A1 (en
Inventor
Melinda Joy Hope Miller
Warren Jaye Porter
Jon Kevin Reel
Almudena Rubio-Esteban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA2694209A1 publication Critical patent/CA2694209A1/en
Application granted granted Critical
Publication of CA2694209C publication Critical patent/CA2694209C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2694209A 2007-08-14 2008-08-04 Azepine derivatives as gamma-secretase inhibitors Expired - Fee Related CA2694209C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95572007P 2007-08-14 2007-08-14
US60/955,720 2007-08-14
PCT/US2008/072049 WO2009023453A1 (en) 2007-08-14 2008-08-04 Azepine derivatives as gamma-secretase inhibitors

Publications (2)

Publication Number Publication Date
CA2694209A1 CA2694209A1 (en) 2009-02-19
CA2694209C true CA2694209C (en) 2013-09-17

Family

ID=39811736

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2694209A Expired - Fee Related CA2694209C (en) 2007-08-14 2008-08-04 Azepine derivatives as gamma-secretase inhibitors

Country Status (11)

Country Link
US (1) US8188069B2 (pt-PT)
EP (1) EP2178844A1 (pt-PT)
JP (1) JP5385904B2 (pt-PT)
KR (1) KR101136260B1 (pt-PT)
CN (1) CN101778826B (pt-PT)
AU (1) AU2008287124B2 (pt-PT)
BR (1) BRPI0815135A2 (pt-PT)
CA (1) CA2694209C (pt-PT)
EA (1) EA017286B1 (pt-PT)
MX (1) MX2010001754A (pt-PT)
WO (1) WO2009023453A1 (pt-PT)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094836B1 (en) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
CA2743436C (en) 2008-11-24 2017-10-31 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
US20130060023A1 (en) * 2011-09-07 2013-03-07 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
WO2014039781A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye & Ear Infirmary Treating hearing loss
CN104822677A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 氟烷基-1,4-苯并二氮杂*酮化合物
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
CN104854097A (zh) 2012-09-21 2015-08-19 百时美施贵宝公司 N-取代的二(氟烷基)-1,4-苯并二氮杂*酮化合物
CN104854094A (zh) 2012-09-21 2015-08-19 百时美施贵宝公司 氟烷基二苯并二氮杂*酮化合物
WO2014047369A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
EP2897960B1 (en) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
US9273075B2 (en) 2012-09-21 2016-03-01 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
US9242941B2 (en) 2012-09-21 2016-01-26 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
WO2014047397A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors
JP2016515625A (ja) 2013-04-04 2016-05-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 増殖性疾患を治療するための併用療法
WO2015073524A1 (en) * 2013-11-12 2015-05-21 Drexel University Novel methods of treating or preventing alzheimer's disease
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
US11466252B2 (en) 2016-01-29 2022-10-11 Massachusetts Eye And Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
EP3442529B1 (en) 2016-04-12 2021-05-26 Eli Lilly and Company Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer
KR102418766B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법
CA3024424A1 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
IL263110B (en) 2016-05-20 2022-07-01 Lilly Co Eli Combined treatment of notch and pd-1 or pd-l1 inhibitors
WO2018071307A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
RU2757276C2 (ru) 2016-12-16 2021-10-12 Пайплайн Терапьютикс, Инк. Способы лечения кохлеарной синаптопатии
WO2018151836A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
CN112384531B (zh) 2018-06-01 2024-05-14 诺华股份有限公司 针对bcma的结合分子及其用途
TW202115114A (zh) 2019-06-24 2021-04-16 瑞士商諾華公司 針對靶向ｂ細胞成熟抗原的多特異抗體之給藥方案及組合療法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319239T3 (es) * 1996-12-23 2009-05-05 Elan Pharmaceuticals, Inc. Cicloalquilo, lactama, lactona y compuestos relacionados, composiciones farmaceuticas que comprenden los mismos y procedimientos para inhibir la liberacion del peptido beta-amiloide y/o sintesis mediante el uso de tales compuestos.
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
US7342007B2 (en) * 2003-03-14 2008-03-11 Astrazeneca Ab Lactams and uses thereof

Also Published As

Publication number Publication date
US8188069B2 (en) 2012-05-29
AU2008287124A1 (en) 2009-02-19
JP2010536766A (ja) 2010-12-02
CN101778826A (zh) 2010-07-14
EA201070278A1 (ru) 2010-06-30
KR20100032924A (ko) 2010-03-26
MX2010001754A (es) 2010-05-14
JP5385904B2 (ja) 2014-01-08
EP2178844A1 (en) 2010-04-28
CA2694209A1 (en) 2009-02-19
CN101778826B (zh) 2012-10-31
WO2009023453A1 (en) 2009-02-19
KR101136260B1 (ko) 2012-04-19
EA017286B1 (ru) 2012-11-30
BRPI0815135A2 (pt) 2015-02-03
AU2008287124B2 (en) 2013-06-06
US20100197660A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
CA2694209C (en) Azepine derivatives as gamma-secretase inhibitors
CA2427227C (en) Lactam compound
US7468365B2 (en) Lactam compound
JP6810285B2 (ja) ５−メチル−１，３，４−オキサジアゾール−２−イル化合物
AU2002243192A1 (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
JP2010517954A (ja) ６−オキソ−６，７−ジヒドロ−５Ｈ−ジベンゾ［ｂ，ｄ］アゼピン−７−イル誘導体
EP1353910B1 (en) Lactam compound
AU2002224321A1 (en) Lactam compound
EP3172206B1 (en) Pyridyl-triazabicycles
WO1999032453A1 (en) POLYCYCLIC α-AMINO-⊂-CAPROLACTAMS AND RELATED COMPOUNDS
CA2390376A1 (en) .beta.-aminoacid compounds useful for inhibiting .beta.-amyloid peptide release and/or its synthesis
CA2425558C (en) Lactam compound
US6958330B1 (en) Polycyclic α-amino-ε-caprolactams and related compounds
US20040077627A1 (en) Lactam compound

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150804